We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
The human microplastic burden and brain health: From measurement to pathophysiology and removal
Summary
This review paper pulls together current research showing that tiny plastic particles are building up in human brain tissue at much higher levels than in organs like the liver or kidney—and that levels have jumped 50% in less than a decade, with the highest amounts found in people who had dementia. Scientists think ultra-processed foods (which make up over half of what many Americans eat) are a major way these plastics get into our bodies, since packaging and processing can shed particles directly into food. While this doesn't prove plastics cause dementia, the pattern is concerning enough that researchers are calling for urgent attention, especially for pregnant women, kids, and people with
Microplastics and nanoplastics now contaminate every human compartment examined, including blood, placenta, atheromatous plaque, and brain tissue. The brain warrants particular attention. Decedent brain tissue has been shown to carry microplastic concentrations seven to thirty times higher than liver or kidney, with a 50% rise documented between 2016 and 2024, and the highest burdens observed in donors with diagnosed dementia. Animal data confirm that nanoscale particles cross the blood-brain barrier within hours of oral exposure. Ultra-processed foods, which now account for more than half of caloric intake in the United States, serve as high-throughput delivery vehicles for microplastics via packaging migration, mechanical processing, and contamination. They have themselves been independently linked in large prospective cohorts to depression, anxiety, cognitive decline, stroke, and dementia. The convergence of high tissue burden, biologically plausible mechanism, and a population-scale modifiable exposure vehicle defines a Brain Health emergency. We outline what is known, what is not yet measurable, and where the field must move next, with attention to vulnerable populations including pregnant women, children, and patients with established neurological or cardiovascular disease.